Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBT002 in Healthy Volunteers and COPD Patients
NCT07288554Phase 1Recruiting
- Sponsor
- Bambusa Therapeutics
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BBT002 in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Bambusa Therapeutics. Primary endpoints: Adverse Events at Day 169, Laboratory Assessments at Day 169 and 3 more. Started Sep 2025; status: recruiting.
02
Drugs
BBT002
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07288554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07288554.